BHVN

Quote

Short

News

Articles

Message Board

Biohaven Ltd. (NYSE : BHVN ) News

News Releases

BHVN News Releases

July 09, 2026 05:00:00 pm

PR Newswire

Biohaven Announces Scientific Leadership Transitions

June 30, 2026 07:30:00 am

PR Newswire

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

June 29, 2026 07:30:00 am

PR Newswire

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

June 29, 2026 07:15:08 am

KlickAnalytics

Underperform Recommendation Issued On BHVN By Bank of America Securities

June 18, 2026 03:28:24 pm

SeekingAlpha

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

June 02, 2026 10:20:39 am

SeekingAlpha

These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations

June 01, 2026 07:30:00 am

PR Newswire

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

May 27, 2026 03:12:22 pm

SeekingAlpha

Biohaven: Despite Today's Gains, I Remain Skeptical

May 27, 2026 07:30:00 am

PR Newswire

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

May 26, 2026 07:30:00 am

PR Newswire

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account